Dizal Pharmaceutical's Hong Kong IPO Prospectus Lapses

Stock News

昨天

The Hong Kong IPO prospectus submitted by Dizal Pharmaceutical Co.,Ltd. (688192.SH) on January 23, 2026, has lapsed as of July 23, 2026, after being active for six months. Goldman Sachs and Huatai International were the joint sponsors at the time of filing.

According to the prospectus, Dizal Pharmaceutical is a commercial-stage biopharmaceutical company focused on oncology and hematological diseases. Its marketed product, Sunvozertinib®, is the only small-molecule epidermal growth factor receptor tyrosine kinase inhibitor globally approved for treating non-small cell lung cancer with EGFR exon 20 insertion mutations.

For the fiscal year 2023, the fiscal year 2024, and the nine months ended September 30, 2025, the company reported revenues of approximately RMB 91.3 million, RMB 360 million, and RMB 586 million, respectively.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1159047255"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1159047255\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1159047255?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-23 10:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159047255","market":"us","top_or_hot":-1,"title":"Dizal Pharmaceutical's Hong Kong IPO Prospectus Lapses","media":"Stock News","content":"<p>The Hong Kong IPO prospectus submitted by <b>Dizal Pharmaceutical Co.,Ltd.</b> (688192.SH) on January 23, 2026, has lapsed as of July 23, 2026, after being active for six months. Goldman Sachs and Huatai International were the joint sponsors at the time of filing.<br><br>According to the prospectus, Dizal Pharmaceutical is a commercial-stage biopharmaceutical company focused on oncology and hematological diseases. Its marketed product, Sunvozertinib®, is the only small-molecule epidermal growth factor receptor tyrosine kinase inhibitor globally approved for treating non-small cell lung cancer with EGFR exon 20 insertion mutations.<br><br>For the fiscal year 2023, the fiscal year 2024, and the nine months ended September 30, 2025, the company reported revenues of approximately RMB 91.3 million, RMB 360 million, and RMB 586 million, respectively.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dizal Pharmaceutical's Hong Kong IPO Prospectus Lapses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDizal Pharmaceutical's Hong Kong IPO Prospectus Lapses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-23 10:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The Hong Kong IPO prospectus submitted by <b>Dizal Pharmaceutical Co.,Ltd.</b> (688192.SH) on January 23, 2026, has lapsed as of July 23, 2026, after being active for six months. Goldman Sachs and Huatai International were the joint sponsors at the time of filing.<br><br>According to the prospectus, Dizal Pharmaceutical is a commercial-stage biopharmaceutical company focused on oncology and hematological diseases. Its marketed product, Sunvozertinib®, is the only small-molecule epidermal growth factor receptor tyrosine kinase inhibitor globally approved for treating non-small cell lung cancer with EGFR exon 20 insertion mutations.<br><br>For the fiscal year 2023, the fiscal year 2024, and the nine months ended September 30, 2025, the company reported revenues of approximately RMB 91.3 million, RMB 360 million, and RMB 586 million, respectively.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REDS","symbol_name":"RPM Republican Senate ETF","start_time":0,"source_url":"","article_id":"1159047255","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159047255","pubTimestamp":1784775187,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"The Hong Kong IPO prospectus submitted by Dizal Pharmaceutical Co.,Ltd. (688192.SH) on January 23, 2026, has lapsed as of July 23, 2026, after being active for six months. Goldman Sachs and Huatai...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","688192":"迪哲医药-U","REDS":"RPM Republican Senate ETF","BK1515":"抗疫概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","FRHC":"Euronext CAC Health Care","09939":"开拓药业-B","BK1574":"生物医药B类股","BK4127":"投资银行业与经纪业","IPOS":"Renaissance International IPO ETF","BK0239":"医药制造","KCE":"SPDR KBW Capital Markets ETF","VXUS":"国际股票ETF-Vanguard","KCAI":"KraneShares China Alpha Index ETF"},"translate_title":"迪扎尔制药香港IPO招股说明书失效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"688192":1,"REDS":1,"IPOS":1,"KCAI":1,"VXUS":1,"FRHC":1,"09939":1,"KCE":1},"content_text":"The Hong Kong IPO prospectus submitted by Dizal Pharmaceutical Co.,Ltd. (688192.SH) on January 23, 2026, has lapsed as of July 23, 2026, after being active for six months. Goldman Sachs and Huatai International were the joint sponsors at the time of filing.According to the prospectus, Dizal Pharmaceutical is a commercial-stage biopharmaceutical company focused on oncology and hematological diseases. Its marketed product, Sunvozertinib®, is the only small-molecule epidermal growth factor receptor tyrosine kinase inhibitor globally approved for treating non-small cell lung cancer with EGFR exon 20 insertion mutations.For the fiscal year 2023, the fiscal year 2024, and the nine months ended September 30, 2025, the company reported revenues of approximately RMB 91.3 million, RMB 360 million, and RMB 586 million, respectively.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}